Oxford BioMedica PLC
Research Oxford BioMedica PLC (OXB) on Bullrun: market cap GBX 636.66M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerOXB
- ExchangeLSE
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyGBX
- Market capGBX 636.66M
- Financial periodFY2025
- RevenueGBP 168.74M
- Revenue growth31.0%
- Net income-GBP 30.13M
- Free cash flow-GBP 4.25M
- Gross margin39.1%
Valuation Snapshot
latest market cap is GBX 636.66M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | GBP 168.74M | -GBP 30.13M | -GBP 4.25M | 39.1% | -26.92 | GBP 96.88M | GBP 148.13M | GBP 91.35M |
| FY2024 | GBP 128.80M | -GBP 43.19M | -GBP 58.16M | 41.2% | -41.75 | GBP 60.65M | GBP 108.76M | GBP 57.05M |
| FY2023 | GBP 89.54M | -GBP 157.49M | -GBP 38.35M | 44.4% | -1.63 | GBP 103.72M | GBP 111.46M | GBP 74.01M |
| FY2022 | GBP 139.99M | -GBP 39.16M | -GBP 28.91M | 49.4% | -0.41 | GBP 141.29M | GBP 114.28M | GBP 204.65M |
| FY2021 | GBP 142.80M | GBP 19.01M | GBP 15.99M | 57.9% | 0.22 | GBP 108.94M | GBP 0 | GBP 187.34M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-23 | GBX 636.66M | n/a | n/a | n/a |
About Oxford BioMedica PLC
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems; InAAVate, a proprietary plug and play' dual-plasmid system for transient transfection, as well as a standard triple transfection system for AAV-based gene therapies.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Oxford BioMedica PLC's market cap?
Oxford BioMedica PLC's market capitalization is GBX 636.66M.
What does Oxford BioMedica PLC do?
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems; InAAVate, a proprietary plug and play' dual-plasmid system for transient transfection, as well as a standard triple transfection system for AAV-based gene therapies.